Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2024, Vol. 29 ›› Issue (6): 715-720.doi: 10.12092/j.issn.1009-2501.2024.06.014

Previous Articles    

Research progress of dalpiciclib in treatment of breast cancer

DU Caiying1, QUAN Xianghua2, SUN Caihong1, YUAN Haidan1   

  1. 1 Yanbian University College of Pharmacy, Yanji 133002, Jilin, China; 2 Department of Pharmacy, Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong, China
  • Received:2023-08-31 Revised:2024-03-18 Online:2024-06-26 Published:2024-05-20

Abstract:

As the first domestically originated cell cycle protein-dependent kinase 4/6 inhibitor, dalpiciclib has been approved by the State Drug Administration for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in combination with fulvestrant or aromatase inhibitors. This article focuses on the progress of dalpiciclib research in breast cancer, summarizing the drug's mechanism of action, phase I-III clinical trials, and drug safety issues.

Key words: dalpiciclib, cyclin-dependent kinase 4/6, breast cancer, clinical trials

CLC Number: